Long-term proton pump inhibitor use and gastrointestinal cancer

David Y. Graham, Robert M. Genta

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

Proton pump inhibitors profoundly affect the stomach and have been associated with carcinoid tumors in female rats. There is now sufficient experience with this class of drugs to allow reasonable estimation of their safety in terms of cancer development in humans. Long-term use of proton pump inhibitors is associated with an increase in gastric inflammation and development of atrophy among those with active Helicobacter pylori infections. The actual risk is unknown but is clearly low. However, it can be markedly reduced or eliminated by H. pylori eradication. It is thus recommended that patients being considered for long-term proton pump inhibitor therapy should be tested for H. pylori infection and, if present, this pathogen should be eradicated. Oxyntic cell hyperplasia, glandular dilatations, and fundic gland polyps may develop in patients not infected with H. pylori, but these changes are believed to be reversible and without significant cancer risk.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalCurrent gastroenterology reports
Volume10
Issue number6
DOIs
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Long-term proton pump inhibitor use and gastrointestinal cancer'. Together they form a unique fingerprint.

  • Cite this